Alcoholism; Psychiatry; Smoking; Substance-Related Disorders; Risk Reduction Behavior; Psychiatry and Psychology
Psychiatry: Addictions, Division of | Center for Nicotine and Tobacco Use Research at Yale (CENTURY) | Center for the Translational Neuroscience of Alcoholism | Connecticut Mental Health Center: Division of Substance Abuse | Psychology Section | Psychotherapy Development Center | Smoking Cessation and Alcohol Treatment Research Clinic | Stress & Addiction Clinical Research Program | Substance Abuse Research | Women's Behavioral Health Research, Division of | Yale Tobacco Center of Regulatory Science
The goal of our laboratory is to develop more efficacious treatments for alcohol use disorders and nicotine dependence and to provide the science base for the regulation of tobacco products. Toward this end, we are conducting clinical trials to determine efficacy of medications and behavioral interventions, and laboratory studies to determine the mechanisms underlying the effects of treatment and the underlying nature of the disorder. Research on how flavors, such as methol and sweeteners, influence the use of tobacco products is underway to inform the regulation of tobacco products by the FDA.
Specialized Terms: Medications development for alcoholism and smoking; Risk reduction and young adult drinking; tobacco regulatory science; treatment methodology; patient treatment matching; biomarkers of treatment response
Extensive Research Description
Yale Tobacco Center for Regulatory Science
Clinical trials of varenicline for the treatment of alcohol dependence among smokers and of naltrexone for young adult heavy drinkers
Laboratory studies to evaluate medications for substance use disorders
Validation of biomarkers for monitoring drinking in clinical trials
Secondary analyses to identify moderators and predictors of response to treatments for alcohol dependence using tree based and trajectory analyses
Training of clinician and transdisciplinary scientists
- Gueorguieva, G., Wu R., Tsai W-M; O’Connor, P.G., Fucito L, Zhang H., O’Malley SS . (in press). An analysis of moderators in the COMBINE Study: Identifying subgroups of patients who benefit from acamprosate. European Journal of Neuropsychopharmacology.
- O’Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. (2015) Naltrexone reduces alcohol drinking in young adults: a double-blind, randomized clinical trial of efficacy and safety. Journal of Clinical Psychiatry, 76(2):e207-13. doi: 10.4088/JCP.13m08934.
- O’Malley SS, Gueroguieva R., Wu R., Jatlow, PI. (2015) Acute alcohol consumption elevates serum bilirubin, an endogenous antioxidant. Drug and Alcohol Dependence. 149:87-92.
- Rojewski AM, Toll BA, O'Malley SS. (2013). Menthol Cigarette Use Predicts Treatment Outcomes of Weight-Concerned Smokers. Nicotine Tob Res. 2013 Oct 10. [Epub ahead of print] PubMed PMID: 24113927.
- DeMartini KS, Palmer RS, Leeman RF, Corbin WR, Toll BA, Fucito LM, O'Malley SS. (2012). Drinking Less and Drinking Smarter: Direct and Indirect Protective Strategies in Young Adults. Psychol Addict Behav. 2012 Oct 22. [Epub ahead of print] PMID: 23088406
- Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. (2012). Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biological Psychiatry, 72(10):832-8.PMID: 23088406
- Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl). 2011 Jun;215(4):655-63. PMID: 21221531
- Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. O’Malley, S.S., Krishnan-Sarin, S., McKee, S.A., Leeman, R.F., Cooney, N.L., Meandzija, B., Wu, R., Makuch, R.W. (2009).Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol. 2009 Jun;12(5):589-97.
- Anton, R.F., O’Malley, S.S., Ciraulo, D.A., et al., for the COMBINE Study Research Group (2006). Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial. JAMA, 295:2003-2017
- Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002 Feb;160(1):19-29